Evofem Biosciences, Inc. (EVFM)
OTCMKTS · Delayed Price · Currency is USD
0.0066
-0.0004 (-5.71%)
May 27, 2026, 3:50 PM EST

Evofem Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-6.030.39-8.8652.98-76.7-205.19
Depreciation & Amortization
0.470.630.760.481.021.02
Loss (Gain) From Sale of Assets
00.020.732.510.93-
Stock-Based Compensation
0.110.170.851.193.318.9
Other Operating Activities
3.3-3.781.77-70.85-4.9838.03
Change in Accounts Receivable
0.59-2.65-4.09-4.615.32-5.38
Change in Inventory
-0.16-0.260.062.111.57-0.02
Change in Accounts Payable
0.350.18-0.914.094.47-0
Change in Other Net Operating Assets
1.113.315.813.14-5.3515.99
Operating Cash Flow
-0.25-1.99-3.89-8.97-70.41-146.67
Capital Expenditures
-0.01-0.01-0.01-0-0.34-2.94
Divestitures
-----0.25
Sale (Purchase) of Intangibles
--0.06-0.56---
Investing Cash Flow
-0.01-0.06-0.57-0-0.34-2.69
Short-Term Debt Issued
-0.380.45.64--
Long-Term Debt Issued
-2.43--11.5-
Total Debt Issued
2.812.810.45.6411.5-
Short-Term Debt Repaid
--0.91-0.78---
Long-Term Debt Repaid
----1.15-5.89-
Total Debt Repaid
-1.27-0.91-0.78-1.15-5.89-
Net Debt Issued (Repaid)
1.541.9-0.394.495.61-
Issuance of Common Stock
--50.2957.5581.99
Repurchase of Common Stock
-----0.02-0.33
Other Financing Activities
-0.01-0.01---1.2-0.97
Financing Cash Flow
1.531.894.624.7861.9490.69
Net Cash Flow
1.27-0.160.16-4.2-8.81-58.66
Free Cash Flow
-0.26-2-3.9-8.97-70.75-149.61
Free Cash Flow Margin
-1.27%-9.89%-20.14%-49.25%-420.21%-1814.73%
Free Cash Flow Per Share
-0.00--0.05-0.01-151.84-2142.80
Cash Interest Paid
0.020.020.160.340.71.39
Cash Income Tax Paid
000.0100.030.01
Levered Free Cash Flow
-1.04-5.85-4.33-7.08-37.99-69.98
Unlevered Free Cash Flow
0.69-4.2-2.72-5.43-36.68-67.02
Change in Working Capital
1.90.580.874.736.0210.58
Source: S&P Global Market Intelligence. Standard template. Financial Sources.